3. World Health Organization. Global leprosy situation. Wkly
Epidemiol Rec. 2007;82:225-232.
4. Balagon MV, Cellona RV, Fajardo TT Jr, et al. Detection of
new leprosy cases at a walk-in skin clinic in Cebu City, Philippines,
highlights surveillance.
Int J Dermatol. 1999;38:796-797.
[PubMed: 10561058]
5. Lockwood DN, Suneetha S. Leprosy: too complex a disease for
a simple elimination paradigm.
Bull World Health Organ. 2005;83:230-235.
[PubMed: 15798849]
6. Lechat MF. The epidemiology of health effects of disasters. Epidemiol
Rev 12: 192-198.
7. Bartels P. Tuberculose in der Jüngeren Steinzeit. Arch
Anthropol. 1907;6:243-255.
8. Ruffer MA. Pott’sche Krankeit an Einer Ägyptischen
Mumie aus der Zeit der 21 Dynastie (um 1000 v. Chr.). Zur
Historischen Biol. d. Krankheitserreger. Vol 3. Topelmann:
Giessen; 1910:9-16.
9. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW,
Williams DL. The continuing challenges of leprosy.
Clin
Microbiol Rev. 2006;19:338-381.
[PubMed: 16614253]
10. Monot M, Honore N, Garnier T, et al. On the origin of leprosy.
Science. 2005;308:1040-1042.
[PubMed: 15894530]
11. Mourit AAM. The path of the destroyer: a history of leprosy
in the Hawaiian Islands. Honolulu Star-Bulletin,
1916.
12. McCoy W. History of leprosy in the United States. Am
J Trop Med. 1938;18:19-34.
13. Brody SN. The Disease of the Soul: Leprosy in Medieval
Literature. Ithaca, NY: Cornell University
Press; 1974.
14. Skinsnes OK. Leprosy in society. II. The pattern of concept
and reaction to leprosy in Oriental antiquity.
Lepr Rev. 1964;35:106-122.
[PubMed: 14143115]
15.Leprosy News and Notes. Fifth International Leprosy Congress—1948.
The words “leper” and “leprosy.” Int
J Lepr Other Mycobact Dis. 1948;16:243.
16. Barksdale L, Kim KS. Mycobacterium.
Bacteriol Rev. 1977;41:217-372.
[PubMed: 67839]
17. Wabitsch KR, Meyers WM. Histopathologic observations on
the persistence of
Mycobacterium leprae in the
skin of multibacillary leprosy patients under chemotherapy.
Lepr
Rev. 1988;59:341-346.
[PubMed: 2468983]
18. Kato L. Leprosy associated mycobacteria: implications.
Acta
Leprol. 1989;7:1-6.
[PubMed: 2696318]
19. Rojas-Espinosa O, Løvik M.
Mycobacterium leprae and
Mycobacterium
lepraemurium in domestic and wild animals.
Rev
Sci Tech Off Int Epiz. 2001;20:219-251.
[PubMed: 11288514]
20. Shepard CC. The experimental disease that follows the injection
of human leprosy into footpads of mice.
J Exp Med. 1960;112:445-454.
[PubMed: 19867175]
21. Levy L, Ji B. The mouse foot-pad technique for cultivation
of
Mycobacterium leprae.
Lepr Rev. 2006;77:5-24.
[PubMed: 16715686]
22. Convit J, Pinardi ME. A simple method for the differentiation
of
Mycobacterium leprae from other mycobacteria
through routine staining technics.
Int J Lepr Other Mycobact
Dis. 1972;40:130-132.
[PubMed: 4119114]
23. Gaylord H, Brennan PJ. Leprosy and the leprosy bacillus:
recent developments in characterization of antigens and immunology
of the disease.
Annu Rev Microbiol. 1987;41:645-675.
[PubMed: 2446563]
24. Williams DL, Gillis TP, Booth RJ, Looker D, Watson JD. The
use of a specific DNA probe and polymerase chain reaction for the
detection of
Mycobacterium leprae.
J Infect
Dis. 1990;162:193-200.
[PubMed: 2192005]
25. Melancon-Kaplan J, Hunter SW, McNeil M, et al. Immunological
significance of
Mycobacterium leprae cell walls.
Proc
Natl Acad Sci U S A. 1988;85:1917-1921.
[PubMed: 3279420]
26. Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay
in the leprosy bacillus.
Nature. 2001;409:1007-1011.
[PubMed: 11234002]
27. Brennan PJ, Vissa VD. Genomic evidence for the retention
of the essential mycobacterial cell wall in the otherwise defective
Mycobacterium leprae.
Lepr
Rev. 2001;72:415-428.
[PubMed: 11826478]
28. Eiglmeier K, Parkhill J, Honore N, et al. The decaying genome
of
Mycobacterium leprae.
Lepr Rev. 2001;72:387-398.
[PubMed: 11826475]
29. Hastings RC, Morales MJ. Observations, calculations, and
speculations on the growth and death of M. leprae in
vivo. Int J Lepr Other Mycobact Dis. 1982;50:579-582.
30. Brubaker ML, Meyers WM, Bourland J. Leprosy in children
one year of age and under.
Int J Lepr Other Mycobact Dis. 1985;53:517-523.
[PubMed: 4086915]
31. Girdhar BK, Girdhar A, Ramu G, Desikan KV. Borderline leprosy
(BL) in an infant—report of a case and a brief review.
Lepr
India. 1983;55:333-337.
[PubMed: 6632788]
32. Binford CH, Meyers WM, Walsh GP, Storrs EE, Brown HL. Naturally
acquired leprosy-like disease in the nine-banded armadillo (
Dasypus novemcinctus):
histopathologic and microbiologic studies of tissues.
J
Reticuloendothel Soc. 1977;22:377-388.
[PubMed: 411927]
33. Meyers WM, Binford CH, Walsh GP. Animal models of leprosy.
In: Leive L, Schlessinger D, eds. Microbiology —1984.
Washington, DC: American Society for Microbiology; 1984:307-311.
34. Bechelli LM, Garbajosa PG, Gyi MM, Dominguez VM, Quagliato
R. Site of early skin lesions in children with leprosy.
Bull
World Health Organ. 1973;48:107-111.
[PubMed: 4267841]
35. Leiker DL. On the mode of transmission of
Mycobacterium
leprae.
Lepr Rev. 1977;48:9-16.
[PubMed: 853838]
36. de Wit MY, Douglas JT, McFadden J, Klatser PR. Polymerase
chain reaction for detection of Mycobacterium leprae in
nasal swab specimens. J Clin Microbiol. 1993;31:502-506.
37. Byrd SR, Gelber R, Bermudez LE. Roles of soluble fibronectin
and b
1 integrin receptors in the binding of
Mycobacterium
leprae to nasal epithelial cells.
Clin Immunol
Immunopathol. 1993;69:266-271.
[PubMed: 8242899]
38. Davey TF, Rees RJW. The nasal discharge in leprosy: clinical
and bacteriological aspects.
Lepr Rev. 1974;45:121-134.
[PubMed: 4608620]
39. Rees RJW, McDougall AC. Airborne infection with
Mycobacterium
leprae in mice.
J Med Microbiol. 1977;10:63-68.
[PubMed: 320339]
40. Pedley JC. The presence of
M. leprae in
human milk.
Lepr Rev. 1967;38:239-242.
[PubMed: 4864195]
41. Duncan ME. Babies of mothers with leprosy have small placentae,
low birth weights and grow slowly.
Br J Obstet Gynaecol. 1980;87:471-479.
[PubMed: 7397079]
42. Duncan ME, Oakey RE. Estrogen excretion in pregnant women
with leprosy: evidence of diminished fetoplacental function.
Obstet Gynecol. 1982;60:82-86.
[PubMed: 7088454]
43. Melsom R, Harboe M, Duncan ME. IgA, IgM and IgG anti-
M.
leprae antibodies in babies of leprosy mothers during the
first two years of life.
Clin Exp Immunol. 1982;49:532-542.
[PubMed: 6756719]
44. Inaba T. Ueber die Histopathologischen und Bakteriologischen
Untersuchungen der Plazenta bei Leprosen. La Lepro. 1938;9(suppl III).
45. Valla MC. Lèpre et grossesse: Thèse
de Médecine. Lyon, France: 1976.
46. Melsom R, Harboe M, Duncan ME, Bergsvik H. IgA and IgM antibodies
against Mycobacterium leprae in cord sera and in patients with leprosy:
an indicator of intrauterine infection in leprosy.
Scand
J Immunol. 1981;14:343-352.
[PubMed: 7038849]
47. Duncan ME, Melsom R, Pearson JM, Menzel S, Barnetson RS.
A clinical and immunological study of four babies of mothers with
lepromatous leprosy, two of whom developed leprosy in infancy.
Int
J Lepr Other Mycobact Dis. 1983;51:7-17.
[PubMed: 6683260]
48. Drutz DJ, Chen TS, Lu WH. The continuous bacteremia of lepromatous
leprosy.
N Engl J Med. 1972;287:159-164.
[PubMed: 4555967]
49. Lane JE, Balagon MV, Dela Cruz EC, et al. Mycobacterium
leprae in untreated lepromatous leprosy: more than skin deep.
Clin
Exp Dermatol. 2006;31:469-470.
[PubMed: 16681612]
50. Kaur I, Kaur S, Sharma VK, Agnihotri N, Vaishnavi C, Ganguly
NK. Bacillaemia and
Mycobacterium leprae cell wall
antigen in paucibacillary leprosy.
Indian J Lepr. 1993;65:283-288.
[PubMed: 8283063]
51. Walsh GP, Meyers WM, Binford CH. Naturally acquired leprosy
in the nine-banded armadillo: a decade of experience 1975–1985.
J
Leukoc Biol. 1986;40:645-656.
[PubMed: 3534127]
52. Walsh GP, Storrs EE, Burchfield HP, Cotrell EH, Vidrine
MF, Binford CH. Leprosy-like disease occurring naturally in armadillos.
J
Reticuloendothel Soc. 1975;18:347-351.
[PubMed: 1214263]
53. Walsh GP, Storrs EE, Meyers W, Binford CH. Naturally acquired
leprosy-like disease in the nine-banded armadillo (
Dasypus
novemcinctus): recent epizootiologic findings.
J
Reticuloendothel Soc. 1977;22:363-367.
[PubMed: 926090]
54. Donham KJ, Leininger JR. Spontaneous leprosy-like disease
in a chimpanzee.
J Infect Dis. 1977;136:132-136.
[PubMed: 886203]
55. Gormus BJ, Xu KY, Alford PL, et al. A serologic study of
naturally acquired leprosy in chimpanzees.
Int J Lepr Other
Mycobact Dis. 1991;59:450-457.
[PubMed: 1890369]
56. Meyers WM, Walsh GP, Brown HL, et al. Leprosy in a mangabey
monkey—naturally acquired infection.
Int J Lepr
Other Mycobact Dis. 1985;53:1-14.
[PubMed: 3889184]
57. Valverde CR, Canfield D, Tarara R, Esteves MI, Gormus BJ.
Spontaneous leprosy in a wild-caught cynomolgus macaque.
Int
J Lepr Other Mycobact Dis. 1998;66:140-148.
[PubMed: 9728446]
58. Meyers WM, Gormus BJ, Walsh GP. Nonhuman sources of leprosy.
Int
J Lepr Other Mycobact Dis. 1992;60:477-480.
[PubMed: 1474287]
59. Walsh GP, Meyers WM, Binford CH, et al. Leprosy as a zoonosis:
an update.
Acta Leprol. 1988;6:51-60.
[PubMed: 3051854]
60. Job CK, Harris EB, Allen JL, Hastings RC. A random survey
of leprosy in wild nine-banded armadillos in Louisiana.
Int
J Lepr Other Mycobact Dis. 1986;54:453-457.
[PubMed: 3528348]
61. Truman RW, Job CK, Hastings RC. Antibodies to the phenolic
glycolipid-1 antigen for epidemiologic investigations of enzootic
leprosy in armadillos (
Dasypus novemcinctus).
Lepr
Rev. 1990;61:19-24.
[PubMed: 2181221]
62. Truman RW, Kumaresan JA, McDonough CM, Job CK, Hastings
RC. Seasonal and spatial trends in the detectability of leprosy
in wild armadillos.
Epidemiol Infect. 1991;106:549-560.
[PubMed: 2050208]
64. Binford CH, Meyers WM, Walsh GP. Leprosy: state of the art.
JAMA. 1982;247:2283-2292.
[PubMed: 7040711]
65. Meyers WM, Gormus BJ, Walsh GP. Experimental leprosy. In:
Hastings RC, ed. Leprosy (Medicine in the Tropics Series). Vol
2. Edinburgh: Churchill Livingstone; 1994:385-408.
66. Meyers WM, Walsh GP, Brown HL, Rees RJ, Convit J. Naturally
acquired leprosy-like disease in the nine-banded armadillo (
Dasypus novemcinctus):
reactions in leprosy patients to lepromins prepared from naturally
infected armadillos.
J Reticuloendothel Soc. 1977;22:369-375.
[PubMed: 336883]
67. Johnstone PAS, Meyers WM, Binford CH. Recent advances in
the development of nonhuman primates as animal models for leprosy. Scand
J Lab Anim Sci. 1989;16(suppl 1):102-105.
68. Wolf RH, Gormus BJ, Martin LN, et al. Experimental leprosy
in three species of monkeys.
Science. 1985;227:529-531.
[PubMed: 3917577]
69. Jacobson RR. Carville and Hansen’s disease control:
past, present and future. Int J Lepr Other Mycobact Dis. 1995;63:272-273.
70. Lane JE, Walsh DS, Meyers WM, Klassen-Fischer MK, Cohen
DJ. Borderline tuberculoid leprosy in a woman with armadillo exposure.
J Am
Acad Dermatol. 2006;55:714-716.
[PubMed: 17010758]
71. Anderson H, Stryjewska B, Boyanton BL, Schwartz MR. Hansen
disease in the United States in the 21st century: a review of the
literature.
Arch Pathol Lab Med. 2007;131:982-986.
[PubMed: 17550332]
72. Harboe M. The work and concepts of Armauer Hansen: how do
they stand today?
Ethiop Med J. 1983;21:123-126.
[PubMed: 6343074]
73. Grant AMB. Leprosy at Nauru since 1928. Int J Lepr
Other Mycobact Dis. 1934;2:305-310.
74. Achilles EG, Hagel C, Vierbuchen M, Dietrich M. Leprosy
accidentally transmitted from a patient to a surgeon in a nonendemic
area. Ann Intern Med. 2004;141:W51.
75. Godal T. Growing points in leprosy research. (3) Immunological
detection of sub-clinical infection in leprosy.
Lepr Rev. 1974;45:22-30.
[PubMed: 4602617]
76. Ryrie GA. Some impressions of Sungei Buloh Leper Hospital
under Japanese occupation.
Lepr Rev. 1947;18:10-17.
[PubMed: 20294503]
77. Skinsnes OK, Higa LH. The role of protein malnutrition in
the pathogenesis of ulcerative “lazarine” leprosy.
Int
J Lepr Other Mycobact Dis. 1976;44:346-358.
[PubMed: 824211]
79. Noussitou FM. Leprosy in Children. Geneva: World
Health Organization; 1976.
80. Feldman RA, Sturdivant M. Leprosy in Louisiana 1855–1970:
an epidemiologic study of long-term trends.
Am J Epidemiol. 1975;102:303-310.
[PubMed: 1101678]
81. Lara CB. Leprosy in children. General considerations: initial
and early changes. Philipp J Lepr. 1966;1:22-57.
82. Shields ED, Russell DA, Pericak-Vance MA. Genetic epidemiology
of the susceptibility to leprosy.
J Clin Invest. 1987;79:1139-1143.
[PubMed: 3549780]
83. Fernando SL, Britton WJ. Genetic susceptibility to mycobacterial
disease in humans.
Immunol Cell Biol. 2006;84:125-137.
[PubMed: 16519730]
84. Fitness J, Tosh K, Hill AV. Genetics of susceptibility to
leprosy.
Genes Immun. 2002;3:441-453.
[PubMed: 12486602]
85. Fitness J, Floyd S, Warndorff DK, et al. Large-scale candidate
gene study of leprosy susceptibility in the Karonga district of
northern Malawi.
Am J Trop Med Hyg. 2004;71:330-340.
[PubMed: 15381816]
86. Hill AV. Aspects of genetic susceptibility to human infectious
diseases.
Annu Rev Genet. 2006;40:469-486.
[PubMed: 17094741]
87. Moraes MO, Cardoso CC, Vanderborght PR, Pacheco AG. Genetics
of host response in leprosy.
Lepr Rev. 2006;77:189-202.
[PubMed: 17171999]
88. Harboe M. The immunology of leprosy. In: Hastings RC, ed. Leprosy
(Medicine in the Tropics Series). Edinburgh: Churchill
Livingstone; 1985:53-87.
89. Siddiqui MR, Meisner S, Tosh K, et al. A major susceptibility
locus for leprosy in India maps to chromosome 10p13.
Nat
Genet. 2001;27:439-441.
[PubMed: 11279529]
90. Shaw MA, Donaldson IJ, Collins A, et al. Association and
linkage of leprosy phenotypes with HLA class II and tumor necrosis
factor genes.
Genes Immun. 2001;2:196-204.
[PubMed: 11477474]
91. Santos AR, Suffys PN, Vanderborght PR, et al. Role of tumor
necrosis factor-alpha and interleukin-10 promoter gene polymorphisms
in leprosy.
J Infect Dis. 2002;186:1687-1691.
[PubMed: 12447749]
92. Roy S, McGuire W, Mascie-Taylor CG, et al. Tumor necrosis
factor promoter polymorphism and susceptibility to lepromatous leprosy.
J Infect
Dis. 1997;176:530-532.
[PubMed: 9237725]
93. Cooke GS, Hill AV. Genetics of susceptibility to human infectious
disease.
Nat Rev Genet. 2001;2:967-977.
[PubMed: 11733749]
94. van Eden W, de Vries RR, D’Amaro J, Schreuder I,
Leiker DL, van Rood JJ. HLA-DR-associated genetic control of the
type of leprosy in a population from Surinam. Hum Immunol. 1982;4:343-350.
95. Ottenhoff THM. State of the Art Lectures. Immunology of
leprosy: lessons from and for leprosy.
Int J Lepr Other
Mycobact Dis. 1994;62:108-121.
[PubMed: 8189076]
96. Mira MT, Alcais A, Van Thuc N, et al. Chromosome 6q25 is
linked to susceptibility to leprosy in a Vietnamese population.
Nat
Genet. 2003;33:412-415.
[PubMed: 12577057]
97. Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy
is associated with PARK2 and PACRG.
Nature. 2004;427:636-640.
[PubMed: 14737177]
98. Schurr E, Alcais A, Singh M, Mehra N, Abel L. Mycobacterial
infections: PARK2 and PACRG associations in leprosy. Tissue
Antigens. 2007;69(suppl 1):231-233.
99. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors
in the pathogenesis and treatment of dermatological disease.
J
Invest Dermatol. 2005;125:1-8.
[PubMed: 15982296]
100. Rook GA, Martinelli R, Brunet LR. Innate immune responses
to mycobacteria and the downregulation of atopic responses.
Curr
Opin Allergy Clin Immunol. 2003;3:337-342.
[PubMed: 14501431]
101. Kang TJ, Yeum CE, Kim BC, You EY, Chae GT. Differential
production of interleukin-10 and interleukin-12 in mononuclear cells
from leprosy patients with a toll-like receptor 2 mutation.
Immunology. 2004;112:674-680.
[PubMed: 15270740]
102. Kang TJ, Lee SB, Chae GT. A polymorphism in the toll-like
receptor 2 is associated with IL-12 production from monocyte in
lepromatous leprosy.
Cytokine. 2002;20:56-62.
[PubMed: 12445799]
103. Kang TJ, Chae GT. Detection of toll-like receptor 2 (TLR2)
mutation in the lepromatous leprosy patients.
FEMS Immunol
Med Microbiol. 2001;31:53-58.
[PubMed: 11476982]
104. Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill
AV. Association of NRAMP1 polymorphism with leprosy type but not
susceptibility to leprosy per se in west Africans.
Am J
Trop Med Hyg. 2001;65:733-735.
[PubMed: 11791966]
105. Ranque B, Alcais A, Thuc NV, et al. A recessive major gene
controls the Mitsuda reaction in a region endemic for leprosy.
J
Infect Dis. 2005;192:1475-1482.
[PubMed: 16170767]
106. Alcais A, Sanchez FO, Thuc NV, et al. Granulomatous reaction
to intradermal injection of lepromin (Mitsuda reaction) is linked
to the human NRAMP1 gene in Vietnamese leprosy sibships.
J
Infect Dis. 2000;181:302-308.
[PubMed: 10608779]
107. Smith JH, Folse DS, Long EG, et al. Leprosy in wild armadillos
(
Dasypus novemcinctus) of the Texas Gulf Coast:
epidemiology and mycobacteriology.
J Reticuloendothel Soc. 1983;34:75-88.
[PubMed: 6350581]
108. Lumpkin LR, 3rd, Cox GF, Wolf JE Jr. Leprosy in five armadillo
handlers.
J Am Acad Dermatol. 1983;9:899-903.
[PubMed: 6643788]
109. West BC, Todd JR, Lary CH, Blake LA, Fowler ME, King JW.
Leprosy in six isolated residents of northern Louisiana: time-clustered
cases in an essentially nonendemic area.
Arch Intern Med. 1988;148:1987-1992.
[PubMed: 3046539]
110. Meyers WM, Gormus BJ, Walsh GP, Baskin GB, Hubbard GB.
Naturally acquired and experimental leprosy in nonhuman primates.
Am
J Trop Med Hyg. 1991;44:24-27.
[PubMed: 2042709]
111. Walsh DS, Meyers WM, Portaels F, et al. High rates of apoptosis
in human
Mycobacterium ulcerans culture-positive
Buruli ulcer skin lesions
Am J Trop Med Hyg. 2005;73:410-415.
[PubMed: 16103613]
112. Walsh DS, Lane JE, Abalos RM, Myint KS. TUNEL and limited
immunophenotypic analyses of apoptosis in paucibacillary and multibacillary
leprosy lesions.
FEMS Immunol Med Microbiol. 2004;41:265-269.
[PubMed: 15196577]
113. Cree IA, Gardiner CA, Beck JS, Mehta J. Studies of cell
death (apoptosis) and cell division in leprosy granulomas.
Int
J Lepr Other Mycobact Dis. 1986;54:607-613.
[PubMed: 3819530]
114. Cree IA, Nurbhai S, Milne G, Beck JS. Cell death in granulomata:
the role of apoptosis.
J Clin Pathol. 1987;40:1314-1319.
[PubMed: 3320094]
115. Dockrell DH. Apoptotic cell death in the pathogenesis of
infectious diseases.
J Infect. 2001;42:227-234.
[PubMed: 11545564]
116. Meyers WM, Kvernes S, Binford CH. Comparison of reactions
to human and armadillo lepromins in leprosy.
Int J Lepr
Other Mycobact Dis. 1975;43:218-225.
[PubMed: 1240870]
117. Mitsuda K. On the value of a skin reaction to a suspension
of leprous nodules. Int J Lepr Other Mycobact Dis. 1953;21:347-358. (In Japanese: Hifuka
Hinyoka Zasshi [Jpn. J Dermatol
Urol] 1919;19:697-708).
118 Guinto RS, Doull JA, Mabalay EB. The Mitsuda reaction in
persons with and without household exposure to leprosy. Int
J Lepr. 1955;23:135-138.
119. Convit J, Avila JL, Goihman M, Pinardi ME. A test for the
determination of competency in clearing bacilli in leprosy patients.
Bull
World Health Organ. 1972;46:821-826.
[PubMed: 4561454]
120. Schlesinger LS, Horwitz MA. Complement receptors and complement
component C3 mediate phagocytosis of Mycobacterium tuberculosis and Mycobacterium
leprae. Int J LeprOther Mycobact
Dis. 1990;58:200-201.
121. Bullock WE. Studies of immune mechanisms in leprosy. I.
Depression of delayed allergic response to skin test antigens. N
Engl J Med. 1968;278:298-304.
122. Walsh DS, Villahermosa LG, Balagon MV, et al. Cutaneous
delayed-type hypersensitivity responsiveness in lepromatous and
borderline lepromatous leprosy patients as determined by MULTITEST
CMI.
Southeast Asian J Trop Med Public Health. 1999;30:518-526.
[PubMed: 10774662]
123. Myrvang B, Godal T, Ridley DS, Froland SS, Song YK. Immune
responsiveness to
Mycobacterium leprae and other
mycobacterial antigens throughout the clinical and histopathological
spectrum of leprosy.
Clin Exp Immunol. 1973;14:541-553.
[PubMed: 4583777]
124. Dwyer JM, Bullock WE, Fields JP. Disturbances of the blood:
T:B lymphocyte ratio in lepromatous leprosy.
N Engl J Med. 1973;288:1036-1039.
[PubMed: 4540496]
125. Rea TH, Bakke AC, Parker JW, Modlin RL, Horwitz DA. Peripheral
blood T lymphocyte subsets in leprosy.
Int J Lepr Other
Mycobact Dis. 1984;52:311-317.
[PubMed: 6332790]
126. Modlin RL, Hofman FM, Taylor CR, Rea TH. T lymphocyte subsets
in the skin lesions of patients with leprosy.
J Am Acad
Dermatol. 1983;8:182-189.
[PubMed: 6219136]
127. Modlin RL, Melancon-Kaplan J, Young SM, et al. Learning
from lesions: patterns of tissue inflammation in leprosy.
Proc
Natl Acad Sci U S A. 1988;85:1213-1217.
[PubMed: 3257577]
128. Rangdaeng S, Scollard DM, Suriyanon V, Smith T, Thamprasert
K, Theetranont C. Studies of human leprosy lesions in situ using
suction-induced blisters. 1. Cellular components of new, uncomplicated
lesions.
Int J Lepr Other Mycobact Dis. 1989;57:492-498.
[PubMed: 2526190]
129. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective
responses to pathogens: cytokine profiles in leprosy lesions.
Science. 1991;254:277-279.
[PubMed: 1925582]
130. Salgame P, Abrams JS, Clayberger C, et al. Differing lymphokine
profiles of functional subsets of human CD4 and CD8 T cell clones.
Science. 1991;254:279-282.
[PubMed: 1681588]
131. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense
mechanisms triggered by microbial lipoproteins through Toll-like
receptors.
Science. 1999;285:732-736.
[PubMed: 10426995]
132. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate
immunity on microbial pathogens.
N Engl J Med. 1999;340:1834-1835.
[PubMed: 10362831]
133. Mehra V, Mason LH, Rothman W, Reinherz E, Schlossman SF,
Bloom BR. Delineation of a human T cell subset responsible for lepromin-induced
suppression in leprosy patients.
J Immunol. 1980;125:1183-1188.
[PubMed: 6997379]
134. Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity
of the major specific glycolipid antigen of
Mycobacterium
leprae.
J Biol Chem. 1982;257:15072-15078.
[PubMed: 6184369]
135. Mehra V, Brennan PJ, Rada E, Convit J, Bloom BR. Lymphocyte
suppression in leprosy induced by unique
M. leprae glycolipid.
Nature. 1984;308:194-196.
[PubMed: 6366573]
136. Prasad HK, Mishra RS, Nath I. Phenolic glycolipid-I of
Mycobacterium
leprae induces general suppression of in vitro concanavalin
A responses unrelated to leprosy type.
J Exp Med. 1987;165:239-244.
[PubMed: 3540178]
137. Turk JL. Cell-mediated immunological processes in leprosy. Lepr
Rev. 1970;41:207-222.
138. Kaplan G, Sampaio EP, Walsh GP, et al. Influence of
Mycobacterium
leprae and its soluble products on the cutaneous responsiveness
of leprosy patients to antigen and recombinant interleukin 2.
Proc
Natl Acad Sci U S A. 1989;86:6269-6273.
[PubMed: 2668961]
139. Horwitz MA, Levis WR, Cohn ZA. Defective production of
monocyte-activating cytokines in lepromatous leprosy.
J
Exp Med. 1984;159:666-678.
[PubMed: 6366107]
140. Haregewoin A, Godal T, Mustafa AS, Belehu A, Yemaneberhan
T. T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy.
Nature. 1983;303:342-344.
[PubMed: 6602296]
141. Nogueira N, Kaplan G, Levy E, et al. Defective gamma interferon
production in leprosy. Reversal with antigen and interleukin 2.
J
Exp Med. 1983;158:2165-2170.
[PubMed: 6417263]
142. Modlin RL, Hofman FM, Horwitz DA, et al. In situ identification
of cells in human leprosy granulomas with monoclonal antibodies
to interleukin 2 and its receptor.
J Immunol. 1984;132:3085-3090.
[PubMed: 6327818]
143. Kaplan G, Mathur NK, Job CK, Nath I, Cohn ZA. Effect of
multiple interferon gamma injections on the disposal of
Mycobacterium
leprae.
Proc Natl Acad Sci U S A. 1989;86:8073-8077.
[PubMed: 2510159]
144. Villahermosa LG, Abalos RM, Walsh DS, Fajardo TT, Walsh
GP. Recombinant interleukin-2 in lepromatous leprosy lesions: immunological
and microbiological consequences.
Clin Exp Dermatol. 1997;22:134-140.
[PubMed: 9425693]
145. Kaplan G. Recent advances in cytokine therapy in leprosy. J
Infect Dis. 1993;167(suppl 1):S18-S22.
146. Talhari S, Orsi AT, Talhari AC, Souza FH, Ferreira LC.
Pentoxifylline may be useful in the treatment of type 2 leprosy
reaction.
Lepr Rev. 1995;66:261-263.
[PubMed: 7500827]
147. Scollard DM, Joyce MP, Gillis TP. Development of leprosy
and type 1 leprosy reactions after treatment with infliximab: a
report of 2 cases. Clin Infect Dis. 2006;43:e19-e22.
148. Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent
erythema nodosum leprosum with infliximab.
N Engl J Med. 2006;355:739.
[PubMed: 16914716]
149. Bullock WE, Ho MF, Chen MJ. Studies of immune mechanisms
in leprosy. II. Quantitative relationships of IgG, IgA, and IgM
immunoglobulins.
J Lab Clin Med. 1970;75:863-870.
[PubMed: 4192266]
150.Navalkar RG, Norlin M, Ouchterlony O. Characterization of
leprosy sera with various mycobacterial antigens using double diffusion-in-gel analysis.
Int
Arch Allergy. 1965;28:250-260.
[PubMed: 4954986]
151. Gajl-Peczalska KJ, Lim SD, Jacobson RR, Good RA. B lymphocytes
in lepromatous leprosy.
N Engl J Med. 1973;288:1033-1035.
[PubMed: 4572304]
152. Park JY, Cho SN, Youn JK, et al. Detection of antibodies
to human nerve antigens in sera from leprosy patients by ELISA.
Clin
Exp Immunol. 1992;87:368-372.
[PubMed: 1544221]
153. Khanolkar-Young S, Rayment N, Brickell PM, et al. Tumor
necrosis factor-alpha (TNF-alpha) synthesis is associated with the
skin and peripheral nerve pathology of leprosy reversal reactions.
Clin
Exp Immunol. 1995;99:196-202.
[PubMed: 7851011]
154. Groathouse NA, Brown SE, Knudson DL, Brennan PJ, Slayden
RA. Isothermal amplification and molecular typing of the obligate intracellular
pathogen
Mycobacterium leprae isolated from tissues
of unknown origins.
J Clin Microbiol. 2006;44:1502-1508.
[PubMed: 16597883]
155. Chedore P, Broukhanski G, Shainhouse Z, Jamieson F. False-positive
amplified Mycobacterium tuberculosis direct test results for samples
containing
Mycobacterium leprae.
J Clin
Microbiol. 2006;44:612-613.
[PubMed: 16455924]
156. Fiallo P, Williams DL, Chan GP, Gillis TP. Effects of fixation
on polymerase chain reaction detection of Mycobacterium leprae.
J
Clin Microbiol. 1992;30:3095-3098.
[PubMed: 1452690]
157. Ridley DS. Skin Biopsy in Leprosy. 2nd
ed. Basel: Geigy; 1985.
158. Job CK, Chacko CJG. A simplified 6 group classification
of leprosy.
Lepr India. 1982;54:26-32.
[PubMed: 7098440]
159. Mukherjee A, Meyers WM. Endothelial cell bacillation in
lepromatous leprosy: a case report.
Lepr Rev 1987;58:419-424.
[PubMed: 3323754]
160. Wade HW. The histoid variety of lepromatous leprosy.
Int
J Lepr. 1963;31:129-142.
[PubMed: 14086699]
161. Williams DL, Gillis TP. A study of the relatedness of Mycobacterium
leprae isolates using restriction fragment length polymorphism analysis. Acta
Leprol. 1989;7(suppl 1):226-230.
162. Williams DL, Gillis TP. Molecular detection of drug resistance
in
Mycobacterium leprae.
Lepr Rev. 2004;75:118-130.
[PubMed: 15282962]
163. Ridley DS, Jopling WH. Classification of leprosy according
to immunity: a five-group system.
Int J Lepr Other Mycobact
Dis. 1966;34:255-273.
[PubMed: 5950347]
164. Scollard DM. Endothelial cells and the pathogenesis of
lepromatous neuritis: insights from the armadillo model.
Microbes
Infect. 2000;2:1835-1843.
[PubMed: 11165928]
165. Scollard DM, McCormick G, Allen JL. Localization of
Mycobacterium
leprae to endothelial cells of epineurial and perineurial
blood vessels and lymphatics.
Am J Pathol. 1999;154:1611-1620.
[PubMed: 10329613]
166. Rambukkana A, Yamada H, Zanazzi G, et al. Role of alpha-dystroglycan
as a Schwann cell receptor for
Mycobacterium leprae.
Science. 1998;282:2076-2079.
[PubMed: 9851927]
167. Shimoji Y, Ng V, Matsumura K, Fischetti VA, Rambukkana
A. A 21-kDa surface protein of
Mycobacterium leprae binds
peripheral nerve laminin-2 and mediates Schwann cell invasion.
Proc
Natl Acad Sci U S A. 1999;96:9857-9862.
[PubMed: 10449784]
168. Sabin TD, Swift TR, Jacobson RR. Leprosy. In: Dyck PJ,
Thomas PK, Griffin IW, eds. Peripheral Neuropathy. Vol
2. Philadelphia: WB Saunders; 1993:1354-1379.
169. Daniel E, Ffytche TJ, Kempen JH, Sundar Rao PS, Diener-West
M, Courtright P. Incidence of ocular complications in patients with
multibacillary leprosy after completion of a 2 year course of multidrug
therapy.
Br J Ophthalmol. 2006;90:949-954.
[PubMed: 16707521]
170. Daniel E, Ffytche TJ, Sundar Rao PS, Kempen JH, Diener-West
M, Courtright P. Incidence of ocular morbidity among multibacillary
leprosy patients during a 2 year course of multidrug therapy.
Br
J Ophthalmol. 2006;90:568-573.
[PubMed: 16622085]
171. Courtright P, Daniel E, Sundarrao, et al. Eye disease in
multibacillary leprosy patients at the time of their leprosy diagnosis:
findings from the Longitudinal Study of Ocular Leprosy (LOSOL) in
India, the Philippines and Ethiopia.
Lepr Rev. 2002;73:225-238.
[PubMed: 12449887]
172. Hogeweg M, Keunen JE. Prevention of blindness in leprosy
and the role of the Vision 2020 Programme.
Eye. 2005;19:1099-1105.
[PubMed: 16304590]
173. Muir E. Juvenile leprosy. Int J Lepr Other Mycobact
Dis. 1936;4:45-48.
174. Latapi F, Zamora AC. The “spotted” leprosy of
Lucio: an introduction to its clinical and histological study. Int
J Lepr Other Mycobact Dis. 1948;16:421-429.
175. Rea TH, Jerskey RS. Clinical and histologic variations
among thirty patients with Lucio’s phenomenon and pure
and primitive diffuse lepromatosis (Latapi’s lepromatosis).
Int
J Lepr Other Mycobact Dis. 2005;73:169-188.
[PubMed: 16830639]
176. Saul A, Novales J. La lèpre de Lucio-Latapi et le
phénomène de Lucio. Acta Leprol. 1983;92:115-132.
177. Hietaharju A, Croft R, Alam R, Birch P, Mong A, Haanpaa
M. Chronic neuropathic pain in treated leprosy.
Lancet. 2000;356:1080-1081.
[PubMed: 11009148]
178. Sethi SK, Solanki RS, Mendiratta V. Leprotic nerve abcess. Appl
Radiol. 2006;35:44-47.
179. Roche PW, Theuvenet WL, Britton WJ. Risk factors for type-1
reactions in borderline leprosy patients.
Lancet. 1991;338:654-657.
[PubMed: 1679473]
180. Rook GAW. The immunology of leprosy.
Tubercle. 1983;64:297-312.
[PubMed: 6362155]
181. Cree IA, Coghill G, Subedi AM, et al. Effects of treatment
on the histopathology of leprosy.
J Clin Pathol. 1995;48:304-307.
[PubMed: 7615846]
182. Bhattacharya SN, Chattopadhaya D, Saha K. Tumor necrosis
factor: status in reactions in leprosy before and after treatment.
Int
J Dermatol. 1993;32:436-439.
[PubMed: 8320025]
183. Pesce C, Grattarola M, Menini S, Fiallo P. Cyclooxygenase
2 expression in vessels and nerves in reversal reaction leprosy.
Am
J Trop Med Hyg. 2006;74:1076-1077.
[PubMed: 16760523]
184. Flageul B, Wallach D, Vignon-Pennamen MD, Pennec J, Cottenot
F. Late onset of a reversal reaction in borderline leprosy.
J
Am Acad Dermatol. 1989;20:857-860.
[PubMed: 2654221]
185. Meyers WM. Mycobacterial infections of the skin. In: Doerr
W, Seifert G, eds. Tropical Pathology. 2nd ed.
Berlin: Springer-Verlag; 1995:291-377.
186. Fajardo TT, Abalos RM, dela Cruz EC, et al.
Clofazimine
therapy for lepromatous leprosy: a historical perspective.
Int
J Dermatol. 1999;38:70-74.
[PubMed: 10065616]
187. Pocaterra L, Jain S, Reddy R, et al. Clinical course of
erythema nodosum leprosum: an 11-year cohort study in Hyderabad,
India.
Am J Trop Med Hyg. 2006;74:868-879.
[PubMed: 16687695]
188. Cuevas J, Rodriguez-Peralto JL, Carrillo R, Contreras F.
Erythema nodosum leprosum: reactional leprosy.
Semin Cutan
Med Surg. 2007;26:126-130.
[PubMed: 17544965]
189. Gelber RH, Drutz DJ, Epstein WV, Fasal P. Clinical correlates
of C1Q-precipitating substances in the sera of patients with leprosy.
Am J
Trop Med Hyg. 1974;23:471-475.
[PubMed: 4823798]
190. Modlin RL, Gebhard JF, Taylor CR, Rea TH. In situ characterization
of T lymphocyte subsets in the reactional states of leprosy.
Clin
Exp Immunol. 1983;53:17-24.
[PubMed: 6223731]
191. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of
tumor necrosis factor-alpha and interleukin-1 beta during leprosy
reactional states.
Clin Exp Immunol. 1991;84:103-108.
[PubMed: 2015700]
192. McAdam KP, Anders RF, Smith SR, Russell DA, Price MA. Association
of amyloidosis with erythema nodosum leprosum reactions and recurrent
neutrophil leucocytosis in leprosy.
Lancet. 1975;2:572-573.
[PubMed: 51405]
193. Hussain R, Lucas SB, Kifayet A, et al. Clinical and histological
discrepancies in diagnosis of ENL reactions classified by assessment
of acute phase proteins SAA and CRP.
Int J Lepr Other Mycobact
Dis. 1995;63:222-230.
[PubMed: 7602217]
194. Walsh DS, Prieto-Go D, Abalos RM, et al. Malignant T-cell
lymphoma mimicking lepromatous leprosy.
Clin Exp Dermatol. 2001;26:173-175.
[PubMed: 11298109]
195. Vettom L, Pritze S. Reliability of skin smear results:
experiences with quality control of skin smears in different routine
services in leprosy control programmes.
Lepr Rev. 1989;60:187-196.
[PubMed: 2478853]
196. Gupte MD, Anantharaman DS, Nagaraju B, Kannan S, Vallishayee
RS. Experiences with
Mycobacterium leprae soluble
antigens in a leprosy endemic population.
Lepr Rev. 1990;61:132-144.
[PubMed: 2198413]
197. Cho SN, Chatterjee D, Brennan PJ. A simplified serological
test for leprosy based on a 3,6-di-O-methylglucose-containing synthetic
antigen.
Am J Trop Med Hyg. 1986;35:167-172.
[PubMed: 3080916]
198. Gonzalez-Abreu E, Mora N, Perez M, Pereira M, Perez J,
Gonzalez AB. Serodiagnosis of leprosy in patients’ contacts
by enzyme-linked immunosorbent assay.
Lepr Rev. 1990;61:145-150.
[PubMed: 2377022]
199. Izumi S, Fujiwara T, Ikeda M, Nishimura Y, Sugiyama K,
Kawatsu K. Novel gelatin particle agglutination test for serodiagnosis
of leprosy in the field.
J Clin Microbiol. 1990;28:525-529.
[PubMed: 2182670]
200. Parkash O, Chaturvedi V, Girdhar BK, Sengupta U. A study
on performance of two serological assays for diagnosis of leprosy
patients.
Lepr Rev. 1995;66:26-30.
[PubMed: 7731338]
201. Olcen P, Harboe M, Warndorff T, Belehu A. Antigens of
Mycobacterium
leprae and anti-
M. leprae antibodies in
the urine of leprosy patients.
Lepr Rev. 1983;54:203-216.
[PubMed: 6355725]
202. Young DB, Harnisch JP, Knight J, Buchanan TM. Detection
of phenolic glycolipid I in sera from patients with lepromatous
leprosy.
J Infect Dis. 1985;152:1078-1081.
[PubMed: 3900237]
203. Sung KJ, Kim SB, Choi JH, Koh K, Na DS. Detection of
Mycobacterium
leprae DNA in formalin-fixed, paraffin-embedded samples from
multibacillary and paucibacillary leprosy patients by polymerase
chain reaction.
Int J Dermatol. 1993;32:710-713.
[PubMed: 7693602]
204. van Beers SM, Izumi S, Madjid B, Maeda Y, Day R, Klatser
PR. An epidemiological study of leprosy infection by serology and
polymerase chain reaction. Int J Lepr Other Mycobact Dis. 1994;62:1-9.
205. Browne SG. Onchocercal depigmentation.
Trans R
Soc Trop Med Hyg. 1960;54:325-334.
[PubMed: 13805083]
206. McDougall AC, Waudby H. Dermal microfilariasis and leprosy.
Lepr
Rev. 1977;48:161-168.
[PubMed: 904422]
207. Meyers WM, Connor DH, Harman LE, Fleshman K, Moris R, Neafie
RC. Human streptocerciasis: a clinico-pathologic study of 40 Africans
(Zairians) including identification of the adult filaria.
Am
J Trop Med Hyg. 1972;21:528-545.
[PubMed: 4672721]
208. de Rijk AJ, Gabre S, Byass P, Berhanu T. Field evaluation
of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project—II. Reaction
and neuritis during and after MDT in PB and MB leprosy patients. Lepr
Rev. 1994;65:320-332.
209. Waters MFR. The treatment of leprosy.
Tubercle. 1983;64:221-232.
[PubMed: 6356539]
210. Job CK. The Kellersberger Memorial Lecture, 1983. The lepromin
test and its role in the management of leprosy.
Ethiop Med
J. 1983;21:233-242.
[PubMed: 6354710]
211.Cochrane RG, Davey TF. Leprosy in Theory and Practice.
2nd ed. Bristol, UK: John Wright & Sons; 1964.
212. Fritschi EP. Reconstructive Surgery in Leprosy.
Bristol, UK: John Wright & Sons; 1971.
213. Languillon J, Carayon A. Précis de Léprologie.
Paris: Masson; 1969.
214. Moschella SL. An update on the diagnosis and treatment
of leprosy.
J Am Acad Dermatol. 2004;51:417-426.
[PubMed: 15337986]
215. Shepard CC. Combinations involving
dapsone, rifampicin,
clofazimine and ethionamide in the treatment of
M. leprae infections
in mice.
Int J Lepr Other Mycobact Dis. 1976;44:135-139.
[PubMed: 945234]
216. Dietrich M, Gaus W, Kern P, Meyers WM. An international
randomized study with long-term follow-up of single versus combination
chemotherapy of multibacillary leprosy.
Antimicrob Agents
Chemother. 1994;38:2249-2257.
[PubMed: 7840553]
217. Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM,
Eccles CG. The Promin treatment of leprosy: a progress report. Public
Health Rep. 1943;58:1729-1741.
218. Waters MF. The diagnosis and management of dapsone-resistant
leprosy.
Lepr Rev. 1977;48:95-105.
[PubMed: 331001]
219. Agrawal S, Agarwalla A.
Dapsone hypersensitivity syndrome:
a clinico-epidemiological review.
J Dermatol. 2005;32:883-889.
[PubMed: 16361748]
220. Kar HK, Bhatia VN, Harikrishnan S. Combined clofazimine-
and dapsone-resistant leprosy: a case report.
Int J Lepr
Other Mycobact Dis. 1986;54:389-391.
[PubMed: 3528345]
221. Warndorff Van Diepen T. Clofazimine-resistant leprosy,
a case report. Int J Lepr Other Mycobact Dis. 1982;50:139-142.
223. World Health Organization. Expert Committee on Leprosy.
World Health Organ Tech Rep Ser No. 607. 1977.
224. Bullock WE. Rifampin in the treatment of leprosy. Rev
Infect Dis. 1983;5(suppl 3):S606-S613.
225. Jacobson RR, Hastings RC. Rifampin-resistant leprosy.
Lancet. 1976;2:1304-1305.
[PubMed: 63780]
226. Williams DL, Waguespack C, Eisenach K, et al. Characterization
of rifampin-resistance in pathogenic mycobacteria.
Antimicrob
Agents Chemother. 1994;38:2380-2386.
[PubMed: 7840574]
227. Ellard GA. Rationale of the multidrug regimens recommended
by a World Health Organization Study Group on Chemotherapy of Leprosy
for Control Programs.
Int J Lepr Other Mycobact Dis. 1984;52:395-401.
[PubMed: 6541207]
228. Gatt P. The Malta experience. 1972–1992: 20 years
after starting the eradication project in Malta. Int J Lepr
Other Mycobact Dis. 1993;61.
229. Jopling WH, Ridley MJ, Bonnici E, Depasquale G. A follow-up
investigation of the Malta project.
Lepr Rev. 1984;55:247-253.
[PubMed: 6492985]
230.World Health Organization. Chemotherapy of leprosy for control
programmes. World Health Organ Tech Rep Ser No. 675. 1982.
231. Becx-Bleuminck M. Operational aspects of multidrug therapy.
Int
J Lepr Other Mycobact Dis. 1989;57:540-551.
[PubMed: 2664048]
232. Cellona RV, Balagon MF, dela Cruz EC, et
al. Long-term efficacy of 2 year WHO multiple drug therapy (MDT)
in multibacillary (MB) leprosy patients.
Int J Lepr Other
Mycobact Dis. 2003;71:308-319.
[PubMed: 14763888]
233. Waters MF. Relapse following various types of multidrug
therapy in multibacillary leprosy [editorial].
Lepr
Rev. 1995;66:1-9.
[PubMed: 7731336]
234. Jamet P, Ji B. Relapse after long-term follow up of multibacillary
patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study
Group.
Int J Lepr Other Mycobact Dis. 1995;63:195-201.
[PubMed: 7602214]
235. Jakeman P. Risk of relapse in multibacillary leprosy.
Lancet. 1995;345:4-5.
[PubMed: 7799708]
236. Agrawal A, Pandit L, Dalal M, Shetty JP. Neurological manifestations
of Hansen’s disease and their management.
Clin
Neurol Neurosurg. 2005;107:445-454.
[PubMed: 16202816]
237. Fine PE, Warndorff DK. Leprosy by the year 2000—what
is being eliminated? [editorial].
Lepr
Rev. 1997;68:201-202.
[PubMed: 9364819]
238. Smith WC. We need to know what is happening to the incidence
of leprosy [editorial].
Lepr Rev. 1997;68:195-200.
[PubMed: 9364818]
239. Naafs B. Treatment of leprosy: science or politics?
Trop
Med Int Health. 2006;11:268-278.
[PubMed: 16553906]
240. Villahermosa LG, Fajardo TT Jr, Abalos RM, et al. Parallel
assessment of 24 monthly doses of rifampin,
ofloxacin, and
minocycline
versus two years of World Health Organization multi-drug therapy
for multi-bacillary leprosy.
Am J Trop Med Hyg. 2004;70:197-200.
[PubMed: 14993633]
241. Jopling WH. Handbook of Leprosy. London: William
Heinemann; 1984.
242. Gelber RH, Fukuda K, Byrd S, et al. A clinical trial of
minocycline in lepromatous leprosy.
Br Med J. 1992;304:91-92.
[PubMed: 1737148]
243. Gelber RH, Murray LP, Siu P, Tsang M, Rea TH. Efficacy
of
minocycline in single dose and at 100 mg twice daily for lepromatous
leprosy.
Int J Lepr Other Mycobact Dis. 1994;62:568-573.
[PubMed: 7868955]
244. Grosset JH. Progress in the chemotherapy of leprosy.
Int
J Lepr Other Mycobact Dis. 1994;62:268-277.
[PubMed: 8046266]
245. Ji B, Jamet P, Perani EG, Bobin P, Grosset JH. Powerful
bactericidal activities of clarithromycin and
minocycline against
Mycobacterium leprae in
lepromatous leprosy.
J Infect Dis. 1993;168:188-190.
[PubMed: 8257487]
247. Villahermosa LG, Fajardo TT Jr, Abalos RM, et al. A randomized,
double-blind, double-dummy, controlled dose comparison of
thalidomide
for treatment of erythema nodosum leprosum.
Am J Trop Med
Hyg. 2005;72:518-526.
[PubMed: 15891124]
248. Nery JA, Perisse AR, Sales AM, et al. The use of pentoxifylline
in the treatment of type 2 reactional episodes in leprosy.
Indian
J Lepr. 2000;72:457-467.
[PubMed: 11212480]
249. Welsh O, Gomez M, Mancias C, Ibarra-Leal S, Millikan LE.
A new therapeutic approach to type II leprosy reaction.
Int
J Dermatol. 1999;38:931-933.
[PubMed: 10632777]
250. Recommendations of the International Task Force for Disease
Eradication. MMWR Recomm Rep. 1993;42(RR-16):1-38.
251. Dayal R, Bharadwaj VP. Prevention and early detection of
leprosy in children.
J Trop Pediatr. 1995;41:132-138.
[PubMed: 7636930]
252. Bakker MI, Hatta M, Kwenang A, et al. Prevention of leprosy
using rifampicin as chemoprophylaxis.
Am J Trop Med Hyg. 2005;72:443-448.
[PubMed: 15827283]
253. Bhatki WS, Chullawala RG, Chaturvedi RM, Dixit GM, Deo
MG. Lepromin conversion induced by a ‘sub-unit’ vaccine
from ICRC bacilli.
Indian J Med Res. 1988;87:545-554.
[PubMed: 3071521]
254. Kar HK, Sharma AK, Misra RS, et al. Reversal reaction in
multibacillary leprosy patients following MDT with and without immunotherapy
with a candidate for an antileprosy vaccine, Mycobacterium w.
Lepr
Rev. 1993;64:219-226.
[PubMed: 8231601]
255. Stanford JL, Rook GA, Bahr GM, et al. Mycobacterium vaccae
in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.
Vaccine. 1990;8:525-530.
[PubMed: 2087873]
256. Bhutani LK, Nath I, Mehra NK. Grand round: leprosy. Lancet. 1995;345:697-703.
257. Convit J, Aranzazu N, Ulrich M, Pinardi ME, Reyes O, Alvarado
J. Immunotherapy with a mixture of
Mycobacterium leprae and
BCG in different forms of leprosy and in Mitsuda-negative contacts.
Int
J Lepr Other Mycobact Dis. 1982;50:415-424.
[PubMed: 6763002]
258. Meyers WM, McDougall AC, Fleury RN, Neves R, Reyes O, Binford
CH. Histologic responses in sixty multibacillary leprosy patients
inoculated with autoclaved
Mycobacterium leprae and
live
BCG.
Int J Lepr Other Mycobact Dis. 1988;56:302-309.
[PubMed: 3045226]
259. Gelber RH, Mehra V, Bloom B, et al. Vaccination with pure
Mycobacterium
leprae proteins inhibits
M. leprae multiplication
in mouse footpads.
Infect Immun. 1994;62:4250-4255.
[PubMed: 7927681]
260. Bechelli LM, Garbajosa PG, Gyi MM, et al.
BCG vaccination
of children against leprosy: seven-year findings of the controlled
WHO trial in Burma.
Bull World Health Organ. 1973;48:323-334.
[PubMed: 4270384]
261. Tripathy SR.
BCG trial in leprosy.
Indian J Lepr. 1984;56:686-687.
262. Convit J, Sampson C, Zuniga M, et al. Immunoprophylactic
trial with combined
Mycobacterium leprae/BCG
vaccine against leprosy: preliminary results.
Lancet. 1992;339:446-450.
[PubMed: 1346818]
263. Karonga Prevention Trial Group. Randomized controlled trial
of single
BCG, repeated
BCG, or combined
BCG and killed
Mycobacterium leprae vaccine
for prevention of leprosy and tuberculosis in Malawi.
Lancet. 1996;348:17-24.
264. Ustianowski AP, Lawn SD, Lockwood DN. Interactions between
HIV infection and leprosy: a paradox.
Lancet Infect Dis. 2006;6:350-360.
[PubMed: 16728321]
265. Meeran K. Prevalence of HIV infection among patients with
leprosy and tuberculosis in rural Zambia.
Br Med J 1989;298:364-365.
[PubMed: 2493937]
266. Kashala O, Marlink R, Ilunga M, et al. Infection with human
immunodeficiency virus type 1 (HIV-1) and human T cell lymphotropic viruses
among leprosy patients and contacts: correlation between HIV-1 cross-reactivity
and antibodies to lipoarabinomannan.
J Infect Dis. 1994;169:296-304.
[PubMed: 7906291]
267. Borgdorff MW, van den Broek J, Chum HJ, et al. HIV-1 infection
as a risk factor for leprosy: a case-control study in Tanzania.
Int
J Lepr Other Mycobact Dis. 1993;61:556-562.
[PubMed: 8151186]
268. Kawuma HJS, Bwire R, Adatu-Engwau F. Leprosy and infection
with the human immunodeficiency virus in Uganda: a case-control study.
Int
J Lepr. 1994;62:521-526.
[PubMed: 7868948]
269. Sekar B, Jayasheela M, Chattopadhya D, et al. Prevalence
of HIV infection and high-risk characteristics among leprosy patients
of south India: a case-control study.
Int J Lepr Other Mycobact
Dis. 1994;62:527-531.
[PubMed: 7868949]
270. Janssen F, Wallach D, Khuong MA, et al. [Association
of Hansen’s disease and human deficiency virus infection.
2 cases].
Presse Med. 1988;17:1652-1653.
[PubMed: 2973025]
271. Lamfers EJ, Bastiaans AH, Mravunac M, Rampen FH. Leprosy
in the acquired immunodeficiency syndrome.
Ann Intern Med. 1987;107:111-112.
[PubMed: 3592426]
272. Moran CA, Nelson AM, Tuur SM, Luengu M, Fonseca L, Meyers
WM. Leprosy in five human immunodeficiency virus-infected patients.
Mod
Pathol. 1995;8:662-664.
[PubMed: 8532702]
273. Sampaio EP, Caneshi JR, Nery JA, et al. Cellular immune
response to
Mycobacterium leprae infection in human
immunodeficiency virus-infected individuals.
Infect Immun. 1995;63:1848-1854.
[PubMed: 7729894]
274. Bwire R, Kawuma HJS. Type 1 reactions in leprosy, neuritis
and steroid therapy: the impact of the human immunodeficiency virus.
Trans
R Soc Trop Med Hyg. 1994;88:315-316.
[PubMed: 7974675]
275. Lucas SB. Human immunodeficiency virus and leprosy.
Lepr
Rev. 1993;64:97-103.
[PubMed: 8341127]